Therapeutic treatment of skin disease with recombinant commensal skin microorganisms
The invention relates to methods for treating or preventing abnormal skin conditions in a human in need thereof, comprising administering a cell culture composition comprising a living culture of bacteria comprising at least one engineered strain that produces a recombinant polypeptide for therapeutic treatment of the abnormal skin condition. The invention also relates to pharmaceutical compositions containing, as the active principle, engineered microorganisms expressing non-vaccinogenic pharmacologically active recombinant therapeutic polypeptides in order to treat or prevent abnormal skin conditions.
1. A method of treating or preventing eczema in a human in need thereof, the method comprising administering to said human a living cell culture composition comprising at least one engineered bacterial strain selected from the group consisting of: Bifidobacterium, Brevibacterium, Propionibacterium, Lactococcus, Streptococcus, Staphylococcus, Lactobacillus, Enterococcus, Pediococcus, Leuconostoc , or Oenococcus, and mixtures thereof, wherein the engineered bacterial strain produces a therapeutically effective amount of a recombinant polypeptide comprising (a) a filaggrin amino acid sequence, (b) a secretion signal, and (c) a cell penetrating peptide, for treating or preventing eczema.
2. A method according to claim 1 , wherein the filaggrin amino acid sequence comprises a sequence selected from SEQ ID NO 1, SEQ ID NO 6, SEQ ID NO 8, SEQ ID NO 9, SEQ ID NO 10, SEQ ID NO 12, SEQ ID NO 13, SEQ ID NO 14, SEQ ID NO 15, SEQ ID NO 16, or SEQ ID NO 17, and combinations thereof.
3. The method according to claim 1 , wherein the eczema is a mild eczema, a moderate eczema, a severe eczema, or a hand eczema.
4. The according to claim 1 , wherein the filaggrin amino acid sequence comprises SEQ ID NO 1.
5. The according to claim 1 , wherein the filaggrin amino acid sequence has at least about 75% homology, at least about 80%, at least about 85%, at least about 90%, or at least about 95% homology to SEQ ID NO 1.